Introduction {#S1}
============

Identifying treatment options for neurological and especially neurodegenerative diseases is one of the most pressing tasks of modern biomedicine. In this context, neural cell replacement has emerged as a particularly promising strategy, which has gained further impetus with the availability of massively scalable human PSCs. A key prerequisite for the use of human PSCs in neural repair is the efficient derivation of disease-specific cell populations. Over the last 20 years, numerous *in vitro* differentiation protocols were established. Classically, they involve extrinsic factors such as morphogens to guide the differentiation process toward a specific cell fate, thereby mimicking regionalization processes during nervous system development. This approach has led to significant advances, for instance, for the generation of midbrain dopamine neurons for the treatment of PD ([@B76]; [@B72]). However, the generation of many neural subtypes is frequently complicated by long differentiation times and complex multi-step growth factor-regimens, which often yield cultures exhibiting a high degree of heterogeneity (see also review by [@B147]). Thus, many growth factor-based protocols have to be regarded as insufficiently precise when it comes to fine-tuning the specification of distinct neural subtypes, especially considering future biomedical applications.

Since morphogen-based cell specification finally converges on the activation of specific transcriptional programs, TF overexpression by itself represents an alternative method to guide cell fate acquisition. This idea was further fueled by the ground-breaking discovery by Takahashi and Yamanaka that an ESC-like pluripotent fate can be induced in mouse ([@B144]) and human ([@B143]) somatic cells by overexpressing a combination of four different TFs, namely Oct3/4, Sox2, Klf4 and c-Myc. The introduction of the iPSC reprogramming technology had two major implications for the scientific field: First, the feasibility to reprogram terminally differentiated somatic cells into iPSCs hinted at the potential power of exploiting TF overexpression as a tool to manipulate cell fates more globally. Second, it created the general opportunity to derive neural cells from basically any adult human and thus revealed new avenues for disease modeling and personalized biomedicine.

In line with the first idea is the concept of direct cell fate conversion, i.e., the use of TFs to directly convert one somatic cell type into another without transiting a stable, pluripotent state. In fact, direct cell fate conversion has been achieved far before the iPSC technique was even introduced: [@B27] successfully converted mouse fibroblasts into myoblasts by overexpressing the TF Myod3. As for neurons, it had already been shown by Magdalena Götz and colleagues in the early 2000s that mouse astrocytes can be directly converted into neurons by overexpressing single neural TFs such as Pax6 ([@B54]), Olig2 ([@B17]), Ngn2 and Ascl1 ([@B9]). In 2010, the Wernig lab achieved to derive iNs from mouse fibroblasts via transdifferentiation across germ layers ([@B158]). Although in this case Ascl1 overexpression seemed sufficient to drive neuronal conversion, too, the derivation of mature iNs was most efficient when multiple TFs were used simultaneously, such as the combined expression of Ascl1, Brn2 and Myt1l ([@B158]). This TF cocktail alone ([@B117], [@B118]) or in combination with the bHLH TF NEUROD1 ([@B109]) was shown to suffice for inducing iNs from human fibroblasts. In combination with SOX2, ASCL1 can also convert human non-neural, brain-resident pericytes into functional iNs ([@B66], [@B65]). How broadly TF overexpression can impact the differentiation of PSCs is illustrated by studies of Minoru Ko and colleagues, who established more than 180 mouse ESC lines, each expressing a distinct TF from the *ROSA* locus after doxycycline induction, which resulted in the specification of a large variety of different somatic cell lineages (in the following also referred to as 'forward programming'; [@B106]; [@B26]; [@B166]).

The aim of this review is to give a comprehensive overview on TF-based approaches for the generation of neural cells ([Figure 1](#F1){ref-type="fig"}). We will speculate on general mechanisms underlying TF-mediated neuronal differentiation and forward programming, specifically comment on current efforts to derive clinically relevant neuronal subtypes and glial cells, and summarize recent endeavors to apply these cells *in vivo* for brain repair. Finally, we will discuss forward programming as an alternative to direct cell fate conversion, and comment on the achievements as well as remaining hurdles for biomedical translation.

![Transcription factor-mediated specification of pluripotent stem cells and neural precursor cells. PSCs, such as ESCs derived from the blastocyst or iPSCs reprogrammed from somatic cells, as well as primary or PSC-derived NPCs can be differentiated into neurons, astrocytes and oligodendrocytes via overexpression of cell type-specific TFs. By using subtype- and/or region-specific TFs, forward programming approaches can be further refined to yield highly specified neuronal subtypes as for instance midbrain dopaminergic neurons. The TFs listed for the derivation of diverse neural cell types were either used alone or in combination. Further details on TF combinations are provided in the main text and in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}.](fncel-14-00121-g001){#F1}

Derivation of Neural Cell Types Via Forward Programming {#S2}
=======================================================

Specifying cell fates by TF overexpression is comparably easy to accomplish within one lineage, especially when starting from cell types which are direct progenitors of the target cell type. Almost 20 years ago, [@B141] reported about the successful derivation of neurons by retrovirally overexpressing the pro-neural bHLH TF Ngn1 in primary rat cortical NPCs ([Table 1](#T1){ref-type="table"}). Since then, other TFs belonging to the bHLH family have been shown to be capable of forcing neuronal differentiation from different NPC populations. These TFs include various Ngns such as Ngn1 ([@B130]; [@B136]), Ngn2 ([@B42]; [@B130]; [@B11]; [@B56]; [@B82]) and Ngn3 ([@B130]), Ascl1 ([@B42]; [@B68]; [@B130]; [@B82]; [@B8]) as well as Neurod TFs ([@B57]).

###### 

Transcription factors used for promoting neuronal differentiation of neural precursor cells and pluripotent stem cells *in vitro*.

  Desired cell type      Starting cell type                              Species           Transcription factor used for forward programming                                                   References
  ---------------------- ----------------------------------------------- ----------------- --------------------------------------------------------------------------------------------------- ----------------
  Neurons (generic)      NPCs                                            Mouse             Pax6                                                                                                [@B50]
                         NPCs                                            Mouse             Sox1                                                                                                [@B64]
                         NPCs                                            Mouse             Dominant-negative form of REST                                                                      [@B48]
                         NPCs                                            Mouse             Ascl1 or Ngn2                                                                                       [@B42]
                         NPCs                                            Mouse             Ngn2                                                                                                [@B11]
                         NPCs                                            Mouse             Sox4                                                                                                [@B12]
                         NPCs                                            Mouse             Zeb2                                                                                                [@B169]
                         NPCs                                            Rat               Ngn1                                                                                                [@B141]
                         NPCs                                            Rat               Neurod                                                                                              [@B57]
                         NPCs                                            Rat               Brn4                                                                                                [@B133]
                         NPCs                                            Rat               Brn4                                                                                                [@B145]
                         NPCs (under glia-promoting conditions)          Rat               Dominant-negative form of REST                                                                      [@B30]
                         ESC-derived NPCs                                Mouse and human   Dlk1                                                                                                [@B142]
                         NPCs                                            Human             ASCL1                                                                                               [@B68]
                         NPCs                                            Human             ASCL1 or NGN1 or NGN2 or NGN3                                                                       [@B130]
                         NPCs                                            Human             ASCL1 or NGN2 or ASCL1+NGN2                                                                         ^(1)^ [@B82]
                         NPCs (primary and ESC-derived)                  Human             shREST or shHAUSP                                                                                   [@B58]
                         iPSC-derived NPCs                               Human             NGN2                                                                                                [@B56]
                         iPSC-derived NPCs                               Human             ASCL1+DLX2                                                                                          [@B8]
                         ESCs                                            Mouse             Neurod1 or Neurod2 or Neurod3                                                                       [@B108]
                         ESCs                                            Mouse             Ngn1                                                                                                [@B154]
                         ESCs                                            Mouse             Ngn2                                                                                                [@B151]
                         ESCs                                            Mouse             Ascl1 or Smad7 or Nr2f1                                                                             [@B165]
                         ESCs                                            Mouse             Multiple (TF screen)                                                                                [@B149]
                         ESCs                                            Mouse             Neurod1                                                                                             [@B112]
                         ESCs                                            Mouse             Multiple (TF screen)                                                                                [@B88]
                         ESCs                                            Mouse             sh-lnc-RNA-1604+Zeb1 and/or Zeb2                                                                    [@B163]
                         ESCs                                            Mouse             Ngn2 or Ascl1                                                                                       [@B3]
                         PSCs                                            Human             ASCL1+ BRN2+MYT1L                                                                                   [@B109]
                         PSCs                                            Human             NGN2 or NEUROD1                                                                                     ^(3)^ [@B172]
                         ESCs                                            Human             ASCL1                                                                                               [@B21]
                         iPSCs                                           Human             FOXG1+SOX2+ASCL1+DLX5+LHX6                                                                          [@B23]
                         PSCs                                            Human             ASCL1+DLX2+LHX6+miR9/9\*-124                                                                        ^(6)^ [@B140]
                         iPSCs                                           Human             ASCL1                                                                                               [@B123]
                         iPSCs                                           Human             NGN2                                                                                                [@B124]
                         PSCs                                            Human             ASCL1+DLX2                                                                                          ^(4)^ [@B167]
                         iPSCs                                           Human             NGN2                                                                                                [@B37]
                         PSCs                                            Human             NGN1 or NGN2 or NGN3 or NEUROD1 or NEUROD2                                                          [@B45]
                         ESCs                                            Human             NGN1 or NGN2 or NGN3 or NEUROD1 or NEUROD2                                                          [@B96]
                         PSCs                                            Human             NGN2                                                                                                [@B115]
                         iPSCs                                           Human             NGN2                                                                                                [@B160]
                         PSCs                                            Human             NGN2                                                                                                [@B104]
                         PSCs                                            Human             LHX6                                                                                                ^(5)^ [@B171]
                         ESCs                                            Human             ZEB1                                                                                                ^(2)^ [@B63]
                         iPSCs                                           Human             NGN2                                                                                                [@B100]
                         iPSCs                                           Human             NGN2 or ASCL1+DLX2                                                                                  [@B120]
                         iPSCs                                           Human             NGN2                                                                                                [@B105]
  Dopaminergic neurons   NPCs                                            Mouse             Nurr1                                                                                               [@B135]
                         NPCs                                            Mouse             Foxa2                                                                                               [@B74]
                         NPCs                                            Rat               Nurr1                                                                                               [@B126]
                         NPCs                                            Rat               Nurr1                                                                                               ^(10)^ [@B70]
                         NPCs                                            Rat               Nurr1 or Ascl1+Nurr1 or Nurr1+Ngn1 or Nurr1+Ngn2 or Nurr1+Shh or Nurr1+Bcl-XL or Nurr1+Bcl-XL+Shh   ^(11)^ [@B111]
                         NPCs                                            Rat               Nurr1                                                                                               [@B5]
                         ESC-derived NPCs                                Mouse             Dmrt5                                                                                               [@B41]
                         ESC-derived NPCs                                Mouse             Lmx1a                                                                                               [@B2]
                         ESC-derived NPCs                                Mouse             Lmx1a or En1 or Otx2 or Lmx1a+En1 or Lmx1a+Otx2 or Lmx1a+En1+Otx2 or Lmx1a+En1+Otx2+Foxa2           [@B110]
                         ESC-derived NPCs                                Mouse             Lmx1a+Foxa2 or Lmx1a+Foxa2+Barhl1                                                                   [@B67]
                         PSC-derived NPCs                                Human             PBX1                                                                                                [@B159]
                         ESC-derived NPCs                                Human             ASCL1, FOXA2, LMX1A, NGN2, NURR1, OTX2 and PITX3 (alone or in combination)                          [@B4]
                         ESC-derived NPCs                                Human             LMX1A                                                                                               ^(12)^ [@B38]
                         ESCs                                            Mouse             Nurr1                                                                                               [@B22]
                         ESCs                                            Mouse             Nurr1                                                                                               ^(8)^ [@B69]
                         ESCs                                            Mouse             Gpx1+Nurr1                                                                                          [@B1]
                         iPSCs                                           Mouse             Nurr1+Pitx3                                                                                         [@B127]
                         ESCs                                            Mouse and human   Nurr1+Pitx3                                                                                         ^(9)^ [@B93]
                         PSCs                                            Human             LMX1A                                                                                               ^(13)^ [@B128]
                         iPSCs                                           Human             mAscl1+mNurr1+mLmx1a                                                                                ^(7)^ [@B150]
                         PSCs                                            Human             ATOH1                                                                                               [@B125]
                         iPSCs                                           Human             NGN2 and/or ATOH1                                                                                   [@B164]
  Medium spiny neurons   ESC-derived NPCs                                Human             GSX2+EBF1                                                                                           ^(14)^ [@B32]
  Motor neurons          ESC-derived NPCs                                Mouse             Phox2b or Olig2                                                                                     [@B110]
                         ESC-derived NPCs                                Mouse and human   Phox2a or Phox2b                                                                                    [@B102]
                         ESCs-derived NPCs                               Human             NGN2+ISL1+LHX3                                                                                      [@B55]
                         ESCs                                            Mouse             Ngn2+Isl1+Lhx3 or Ngn2+Isl1+Phox2a                                                                  ^(15)^ [@B99]
                         iPSCs                                           Human             NGN1+NGN2                                                                                           [@B18]
                         PSCs                                            Human             NGN1+NGN2+NGN3+NEUROD1+NEUROD2                                                                      [@B45]
                         PSCs                                            Human             NGN2+ISL1+LHX3                                                                                      [@B46]
                         iPSCs                                           Human             NGN2+ISL1+LHX3 or NGN2+ISL1+PHOX2A                                                                  [@B28]
  Sensory neurons        ESC-derived neural crest progenitors            Human             NGN2                                                                                                [@B129]
                         iPSC-derived neural crest progenitors + iPSCs   Human             NGN2+BRN3A                                                                                          [@B105]
  Otic neurons           (Otic) NPCs                                     Human             NGN1                                                                                                [@B136]
  Serotonergic neurons   ESC-derived NPCs                                Mouse             Nkx2.2                                                                                              [@B110]

Numbers in superscript relate to citations in
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bHLH Transcription Factors as Key Instructors of Neuronal Differentiation {#S2.SS1}
-------------------------------------------------------------------------

Interestingly, also rapid neuronal differentiation of PSCs (this term will be used to describe ESCs and iPSCs together in the following), which are not yet committed to the neural lineage, was shown to be feasible with bHLH TFs. A milestone in the field of neuronal forward programming was reached in 2011, when the groups of Marius Wernig and Thomas Südhof reported that combined overexpression of the TFs Ascl1, Brn2, and Myt1l not only suffices to transdifferentiate mouse fibroblasts into neurons ([@B158]) but also efficiently drives neuronal specification from human PSCs ([@B109]). The authors revealed that ASCL1 is most crucial for neural fate acquisition, whereas the TFs BRN2 and MYT1L rather promote down-stream neuronal maturation. Using the full TF cocktail, electrophysiologically active neurons can be derived from human PSCs after only 6 days of *in vitro* differentiation ([@B109]). Several other labs subsequently demonstrated that Ascl1 alone can efficiently forward program mouse ESCs ([@B165]; [@B149]) and human PSCs ([@B21]; [@B123]) toward a neuronal fate, albeit with slower differentiation dynamics than the full ASCL1, BRN2, and MYT1L TF combination: In mouse ESCs, overexpression of Ascl1 leads to a sharp increase of neural markers within the first 7 days of induction ([@B165]; [@B149]), and 11 days after overexpressing Ascl1, about half of the neurons were shown to generate action potentials upon current injection ([@B165]). In human PSCs, ASCL1-overexpressing cells do not start to express neuronal markers such as TUBB3 and MAP2 before day 9 of differentiation. Still, ASCL1 overexpression alone is sufficient to generate morphologically and functionally mature neurons when ESC-derived immature neuronal cells are cultured in advanced neuronal differentiation medium and are grown on primary glial cells. These neurons not only exhibit mature electrophysiological properties such as spontaneous action potential firing after 4 weeks of differentiation but also respond to exogenous AMPA and GABA application and demonstrate signs of short-term synaptic plasticity, indicating the formation of functional synapses ([@B21]).

Overexpression of other bHLH TFs, too, induces rapid neuronal differentiation of PSCs: In one of the first *in vitro* studies employing overexpression of Ngn1 in mouse ESCs, transduced cells underwent morphological rearrangements forming neurite-like structures already within the first 72 h and became electrophysiologically excitable as early as 4 days after transgene induction ([@B154]). After 5 days of Ngn2 overexpression, mouse ESC-derived cells express the mature neuronal marker Map2, display neuronal electrophysiological properties at day 10, and form synapses in co-culture with primary mouse hippocampal neurons 20 days post induction ([@B151]). The first ground-breaking proof that NGN2 has the same effect in human PSCs was -- again -- provided by the groups of Marius Wernig and Thomas Südhof in 2013. The authors demonstrated that forward programming human PSCs with NGN2 reproducibly yields neurons with almost 100% purity within 2 weeks, and as was observed in mouse cells, these neurons do not only acquire neuronal-like electrophysiological properties but are also capable of functionally integrating into synaptic networks with cortical mouse neurons. Notably, the authors further reported that overexpressing the bHLH TF NEUROD1 can instruct neuronal differentiation from human PSCs, too ([@B172]). Interestingly, already in 2001, [@B108] had investigated the neurogenic effect of Neurod TFs by overexpressing Neurod1, Neurod2, and Neurod3 in mouse ESCs and found that all three Neurods suffice to induce immature neuronal-like cells within 72 h.

More recently, other groups have corroborated the finding that NGN2 overexpression suffices to forward program human PSCs to neurons expressing MAP2 and NEUN within 2 to 10 days of differentiation ([@B124]; [@B45]; [@B96]; [@B115]). Neuronal differentiation can be further accelerated by combined overexpression of NGN1 and NGN2, and in this case, 90% of all cells were found to express MAP2 and the synapse marker synapsin already at day 4 of differentiation. However, additional morphological, transcriptomic, and functional analyses indicate that a majority of the obtained neurons at this early time point are still immature and not yet fully developed ([@B18]). Yet, several labs including our own have revealed that co-culturing NGN2-neurons with glial cells significantly facilitates maturation ([@B172]; [@B18]; [@B100]; [@B120]), and when cultured under appropriate conditions, neurons derived by forward programming can be utilized for sophisticated electrophysical analyses: Cultured on glia microdots, single forward programmed NGN2-neurons form an autaptic system by making synapses onto themselves, which can be used for studying functional features such as synaptic transmission and short-term plasticity ([@B100]; [@B120]), and networks of forward programmed neurons cultured on multielectrode arrays have also been employed for functional analyses ([@B37]; [@B104]).

Mechanisms Underlying bHLH Transcription Factor-Mediated Forward Programming {#S2.SS2}
----------------------------------------------------------------------------

bHLH TFs are named after their common protein structure motif consisting of two α-helices mediating dimerization and a basic domain, which binds to E-box motifs with the consensus sequence CANNTG. The group of bHLH TFs is subdivided according to their ubiquitous versus tissue-specific expression profile, and neural bHLH TFs are further grouped into the *achaete-scute complex* and *atonal* gene families (for further details see review by [@B29]). First hints as of why bHLH TFs might be able to orchestrate neuronal fate acquisition were obtained from NPC-to-neuron differentiation paradigms: Ngn1, for instance, specifically binds to E-box motifs at neuronal genes in rat NPCs, acting as a direct transcriptional activator ([@B141]). In human PSCs, the TFs NGN1, NGN2 and NGN3 seem to even cross-activate each other and induce common pro-neural down-stream targets including other bHLH TFs such as *NEUROD1, NEUROD2* and *NEUROD4* ([@B18]; [@B45]; [@B164]). Such a synergism might not be restricted to the group of NGNs, since the bHLH TF ATOH1 has been shown to induce both, *NGN2* and *NEUROD1* in human PSCs, and was thus used for forward programming of human PSCs into neurons ([@B125]; [@B164]). These observations might indicate that one common mechanism underlying neuronal forward programming of PSCs with bHLH TFs is the activation of a whole network of cross-regulated bHLH TFs, including the induction of more down-stream Neurod TFs. In line with this hypothesis, no difference was reported comparing the neuronal induction potency of NGN1, NGN2, NGN3, NEUROD1, and NEUROD2 in human ESCs ([@B96]).

In order to elucidate the mechanism by which combined NGN1 and NGN2 overexpression drives neuronal fate acquisition of human iPSCs more in depth, [@B18] performed a comprehensive set of experiments dissecting mRNA and miRNA regulation kinetics during the early phase of neural induction. A mRNA network analysis revealed that during the first 4 days of differentiation, destabilization of the pluripotency network is initiated by decreasing *SOX2, NANOG*, and *OCT4* levels, and genes associated with an NPC stage and the gene ontology term 'regulation of neurogenesis' such as *NOTCH1*, *DLL1*, *DLL4*, *HES5*, *FABP7*, and *NTN1* are temporarily upregulated. This phase of NPC marker induction is very brief, though (as was also observed by [@B172]), resulting in a significant downregulation of cell cycle-related genes by day 4, which suggests that PSC-derived cells only traverse a short progenitor-like phase during forward programming. In line with this, neuron-associated genes such as *POU3F2* (also known as *BRN2*), *ZEB1*, *ISL1*, *TLX3*, and *POU4F1* (also known as *BRN3a*) are upregulated already in this early phase of reprogramming, whilst inhibitors of neurogenesis as for instance *REST* and *HES1* are repressed. Concomitant with the dynamics of mRNA regulation, the expression of the pluripotency-associated miRNA cluster 302/367 decreases, whereas the abundance of neuronal miRNAs such as miR124, miR96, and miR9 increases upon differentiation ([@B18]).

The molecular consequences of Neurod1 induction were explicitly investigated by Vijay Tiwari's group in mouse ESCs: Neurod1 overexpression influences chromatin accessibility at its target sites by reducing repressive H3K27me3 marks, increasing H3K27ac and recruiting RNA polymerase II. Hence, during the first 24 h of differentiation, the fraction of enhancer and promotor regions directly bound by Neurod1 probably accounts for approximately 25% of all upregulated genes identified by RNA sequencing. Interestingly, upregulated genes are exclusively enriched for neurogenesis-associated gene ontology terms, and consequently, after 48 h, and even in the presence of the pluripotency-promoting factor Lif, Tubb3 expression is induced. Even transient Neurod1 expression for as short as 48 h suffices to stably remodel the epigenetic and transcriptional landscape at Neurod1 targets, which later drive neuronal differentiation of ESCs even in the absence of Neurod1 ([@B112]). Altogether, these data indicate that activation of the bHLH TF Neurod1 might represent one of the crucial entry points for neural fate acquisition in forward programming paradigms.

Neuronal Forward Programming Factors Beyond the bHLH Family {#S2.SS3}
-----------------------------------------------------------

Neuronal specification from diverse NPC populations can be driven by pro-neural, non-bHLH TFs such as Pax6 ([@B50]), Brn4 ([@B133]; [@B145]) and members of the Sox family of TFs ([@B64]; [@B12]). Furthermore, overexpression of Dlk1 in mouse and human ESC-derived NPCs facilitates neural specification by promoting cell cycle exit via reduction of Notch, and modulation of BMP signaling ([@B142]). Finally, decreasing REST signaling in human NPC lines induces neurogenesis, too ([@B58]), and this can most likely be attributed to REST's function as a transcriptional repressor of neuronal genes such as *Tubb3* ([@B48]) and *Neurod2* ([@B30]).

Considering these observations, it is not surprising that non-bHLH TFs have also been implemented in forward programming of PSCs. [@B165] for instance, identified that doxycycline-mediated induction of Nr2f1 or Smad7 can instruct neuronal differentiation of mouse ESCs. [@B88] further performed a comprehensive CRISPR activation screen in mouse ESCs and revealed that besides the bHLH TFs *Ngn1* and *Tcf15*, also non-bHLH TFs such as *Brn2*, *Foxo1*, *Ezh2* and *Zeb1* have neurogenic potential. Zeb1 and Zeb2, for instance, are homologous TFs and downstream effectors of the lncRNA-1604, which regulates neural differentiation by competitive binding with miRNA-200c in mouse ESCs ([@B163]), and *ZEB1* is also induced after combined overexpression of NGN1 and NGN2 in human iPSCs ([@B18]). Yet, at least for Zeb1 it was shown by other groups that its neuron-promoting effect is comparably weak. When overexpressed in human ESCs, ZEB1 does not immediately decrease pluripotency markers *OCT4, NANOG*, and *SOX2*, and most cells are negative for the early neuronal marker TUBB3 up until day 25 of differentiation ([@B63]). Since it was demonstrated that Zeb2 overexpression decreases *Ngn2* expression in embryonic midbrain cells and a dopaminergic cell line ([@B169]), a negative correlation between these two TFs might account for the observed weak pro-neurogenic effect. Conversely, forward programming by *Ezh2* induction results in the formation of electrophysiological active and synapse-forming neurons, which is comparable to the effect of Ngn1-mediated forward programming. The pro-neurogenic action of Ezh2 might most likely be due to its inhibitory effect on endodermal and mesodermal lineage-associated genes ([@B88]), which is in line with the fact that the methyltransferase Ezh2 is a core component of the PRC2 complex and involved in transcriptional repression.

In sum, these studies hint at some common mechanisms underlying TF-driven specification of NPCs and PSCs into neurons, which include (i) exit of the original cell fate, (ii) repression of alternative lineage decisions, and (iii) activation of a pro-neuronal transcriptional program.

Forward Programming Into Clinically Relevant Neuronal Subtypes {#S2.SS4}
--------------------------------------------------------------

When thinking of forward programming as a tool to produce neural cell types for brain repair, it is particularly relevant to thoroughly characterize the exact phenotype of the obtained cells. Already [@B130] noted that the four different bHLH TFs NGN1, NGN2, NGN3, and ASCL1 had slightly varying effects on neuronal subtype specification from human primary cortical NPCs, although cultures generally consisted of a mixed population of GABAergic, cholinergic, serotoninergic, adrenergic, and MNs ([@B130]). This observation is in line with other reports demonstrating divergent effects for different bHLH TFs on neuronal subtype derivation: Overexpression of ASCL1 induces a GABAergic bias in neuronal cultures differentiating from neurospheres isolated from both human fetal cortex and mesencephalon ([@B68]), whereas NGN2 overexpression in human iPSC-derived NPCs ([@B56]) and PSCs ([@B172]; [@B104]; [@B100]; [@B120]; [@B105]) leads to the derivation of mostly glutamatergic neurons.

### Cortical Glutamatergic and Forebrain GABAergic Neurons {#S2.SS4.SSS1}

The results of multiple independent studies indicate that glutamatergic neurons derived by overexpression of NGN2 adopt a telencephalic fate characterized by the expression of cortical layer II/III markers such as FOXG1, BRN2, SATB2, and *CUX1* ([@B172]; [@B37]; [@B160]; [@B104]; [@B100]). However, there are reports indicating that forward programming with a combination of NGN1 and NGN2 results in neurons co-expressing vGLUT1 and ChAT ([@B18]). Similarly, mRNA-driven combinatorial overexpression of NGN1, NGN2, NGN3, NEUROD1, and NEUROD2 in human PSCs gives rise to a population of remarkably pure cholinergic MNs ([@B45]), indicating that NGN2 can, in particular in combination with additional TFs and morphogens, instruct other fates than glutamatergic neurons (see also section 'Motor and Sensory Neurons').

Ascl1 -- which is expressed in more ventral regions of the telencephalon *in vivo* ([@B20]; [@B36]) -- is alone insufficient to consistently give rise to homogenous cultures of only one specific neuronal subtype and instead results in mixed cultures of MNs, dopaminergic and GABAergic neurons ([@B165]). However, in a landmark study, [@B167] demonstrated that overexpression of ASCL1 in combination with DLX2, a downstream effector of ASCL1, is able to direct human PSCs into remarkably pure cultures of telencephalic forebrain GABAergic neurons. [@B140] used a combination of ASCL1 and DLX2 with LHX6 and a synthetic cluster of miRNA-9/9^∗^ and miRNA-124 (miR9/9^∗^-124), and found that the induced GABAergic neurons express markers reminiscent of derivatives of the medial ganglionic eminence, but not alternative birthplaces such as the lateral ganglionic eminence, caudal ganglionic eminence or the preoptic area. As somatostatin- and parvalbumin-positive inhibitory interneurons appear to play a particular role in several neurological and neuropsychiatric diseases, the generation of these subtypes would be highly desirable. [@B23] reported that combinatorial overexpression of the five TFs FOXG1, SOX2, ASCL1, DLX5, and LHX6 in human iPSCs gives rise to highly enriched cultures of parvalbumin-expressing inhibitory neurons. [@B171] explored overexpression of LHX6 alone and found that 80% of the human PSC-derived neurons were GABAergic, with a fraction of 21% and 29% of the TUBB3-positive neurons co-expressing parvalbumin and somatostatin, respectively. As with forward programmed excitatory neurons, functional maturation of induced GABAergic neurons can be promoted by co-culture with primary rodent glia ([@B140]). Interestingly, this process can also be promoted by co-culture with NGN2-forward programmed excitatory neurons ([@B167]) -- an observation which could suggest that utmost functionality can only be achieved in the context of a heterogenous synaptic network as encountered *in vivo*.

### Midbrain Dopaminergic Neurons {#S2.SS4.SSS2}

Representing a prime target of PD, midbrain dopamine neurons are a particularly attractive donor cell population for neural repair. However, the efficacy of neuroregeneration seems to heavily depend on the fidelity of neuronal subtype specification. This was recently exemplified by [@B73], who revealed that the purity of dopaminergic cell preparations (i.e., the ratio of caudal ventral mesencephalic dopaminergic neurons versus neurons of the diencephalic subthalamic nucleus) is predictive for successful dopaminergic specification and symptom amelioration after transplantation into a mouse model of PD. Although potent extrinsic factor-guided protocols for the derivation of dopaminergic neurons from PSCs exist ([@B76]; [@B72]), there is a necessity to further fine-tune cell fate subspecification. This was nicely illustrated by [@B79], who profiled the developing mouse and human midbrain using single cell RNA sequencing, and delineated multiple molecularly diverse NPC populations and several distinct classes of mature dopaminergic neurons in the midbrain of both species. Notably, the authors compared transcriptomic signatures of human PSC-derived dopaminergic neurons with their *in vivo* counterparts and found that although the morphogen-driven dopaminergic differentiation recapitulated key developmental stages of embryonic dopaminergic lineage specification, the gene expression profile of *in vitro* generated populations still differed from that of native midbrain dopamine neurons. The question remains whether forward programming can further improve the authenticity of specialized dopaminergic neuron subpopulations.

Already beginning in the end of last century, several labs reported that overexpression of the mesencephalic TF Nurr1 in primary adult rat hippocampal NPCs ([@B126]) and primary embryonic rat cortical NPCs ([@B70]; [@B111]; [@B5]) promotes the generation of a midbrain dopamine neuron-like phenotype. A similar effect was communicated for primary mouse NPCs isolated from the ganglionic eminence and midbrain as well as mouse ESC-derived NPCs, whereas NPCs from embryonic cortex and spinal cord as well as adult NPCs from the subventricular zone seemed resistant to the pro-dopaminergic patterning effect of Nurr1 ([@B135]). Other midbrain-specific TFs that were tested for their potency to instruct dopaminergic fates include (i) Foxa2, which, when overexpressed in mouse primary midbrain-derived and ESC-derived NPCs, was found to boost the derivation of TH-positive neurons ([@B74]), (ii) Lmx1a, which efficiently specifies murine Shh- and Fgf8-treated ([@B2]; [@B110]) as well as human ESC-derived NPCs toward a dopaminergic fate ([@B38]), and in combination with Foxa2 and Barhl1 drives dopaminergic differentiation from Fgf8- and CHIR99021-exposed murine ESC-derived NPCs ([@B67]), (iii) En1 and (iv) Otx2, which were reported to drive dopaminergic differentiation of murine NPCs alone, each in combination with Lmx1a, or as a 3 TF cocktail ([@B110]), (v) Dmrt5, which does not increase overall neuronal yield after being overexpressed in mouse ESC-derived dopaminergic NPCs but specifically induces an increase of certain midbrain dopaminergic markers on RNA level ([@B41]), and (vi) PBX1, which appears to cooperate with NURR1 promoting dopaminergic specification from human PSC-derived NPCs ([@B159]). Another good example is the recently published study by [@B4], who used magnetically guided mRNA spot delivery to screen single TFs and TF combinations for their capacity to commit human ESC-derived NPCs toward a dopaminergic fate, and revealed that transfection of FOXA2, LMX1A, and PITX3 mRNA results in an increased yield of TH-positive neurons. Combinatorial delivery of these 3 TFs at their respective most effective stage results in almost 68% of TH- and MAP2-double-positive cells ([@B4]).

Nurr1 was also the first TF explored in the context of forward programming PSCs toward a dopaminergic fate, and its overexpression in mouse ESCs causes a substantial increase in the number of TH-expressing neurons ([@B22]; [@B69]). Exposure to the morphogens Shh and Fgf8 further increases the yield of TH-expressing neurons after Nurr1 overexpression with enrichment in the order of 60% to 80% ([@B22]; [@B69]), and enhances the release of dopamine after induced depolarization ([@B69]). The combination of Nurr1 with other TFs (such as Gpx1), morphogens (as for instance RA) and chemicals (e.g., β-boswellic acid) was reported to boost the yield of dopaminergic neurons, too ([@B1]). Especially the combined expression of Nurr1 and Pitx3 was shown to be beneficial for the derivation of dopaminergic neurons from mouse PSCs ([@B93]; [@B127]). Whereas these TFs alone are sufficient to induce markers expressed early in dopaminergic development such as TH and *Aldh2*, it is only upon co-expression that they synergistically induce more advanced markers such as *Dat* and *Tyrp1* ([@B93]). In this co-expression paradigm, too, addition of Shh and Fgf8 increased the induced secretion of dopamine from these cells ([@B127]). Notably, and in contrast to overexpression of Nurr1 alone ([@B69]), co-expression of Nurr1 and Pitx3 (along with exposure to Shh and Fgf8) prevents the derivation of 'contaminating' cell fates such as serotonergic or GABAergic neurons ([@B93]).

[@B128] analyzed the effect of LMX1A overexpression in human iPSCs and observed a quick down-regulation of *NANOG* with a simultaneous upregulation of *NURR1*, *EN1*, and *TH*, which are all characteristic markers of midbrain dopamine neurons. At day 34 of differentiation, the derived neurons express DAT and TH, show synaptophysin-positive puncta on TH-positive neurites and inducible dopamine release. Although LMX1A overexpression alone enhances the dopaminergic specification of differentiating neurons, it does not result in an increased neuronal yield ([@B128]).

The group of Vania Broccoli explored forced expression of LMX1A together with NURR1 and ASCL1 in order to boost neuronal induction *per se* as well as dopaminergic induction in particular. In their study, lentiviral overexpression of this TF cocktail in human iPSCs gave rise to homogenous neuronal cultures expressing a wide range of proteins associated to the dopaminergic lineage such as TH, DAT, ALDH1A1, and GIRK2. Resulting neurons exhibited neuron-like electrophysiological properties and were able to spontaneously release dopamine after 3 weeks of differentiation. However, although the number of TH- and TUBB3-co-expressing cells doubled when applying the TF cocktail ([@B150]), the overall yield of TH-expressing neurons remained lower as compared to the yield after overexpression of LMX1A alone ([@B128]). This difference might be attributable to the lack of additional patterning molecules such as SHH and FGF8 in the medium used by Vania Broccoli's group, and/or shorter differentiation times till analysis, and thus warrants further studies on forward programming approaches combining neurogenic and regionalizing TFs.

Finally, it is worth mentioning that the bHLH TF ATOH1 is itself able to induce dopaminergic neurons from human PSCs, especially when combined with exposure to SHH and FGF8b. In combination with these morphogens, ATOH1 overexpression yields up to 82% TH-expressing neurons. In addition to *TH*, *FOXA2*, *NURR1*, *LMX1A*, *DAT*, *VMAT2*, and *OTX2* are significantly upregulated during ATOH1-driven differentiation. Characterization of the growth factor-treated, ATOH1-overexpressing neuronal cultures on a functional level demonstrated that these neurons possess electrophysiological properties similar to primary rat midbrain dopaminergic neurons and exhibit dopamine release after electrical stimulation at day 36 of differentiation, suggesting actual functionality ([@B125]). Very recently, this approach was further improved by establishing a protocol based on combined ATOH1 and NGN2 overexpression in human iPSCs via repetitive mRNA transfections ([@B164]).

### Medium Spiny Neurons {#S2.SS4.SSS3}

Another neuronal subtype of particular biomedical interest are MSNs, a GABAergic population abundantly found in the striatum and most prominently affected by HD. In human ESC-derived NPCs treated with SHH and the WNT inhibitor DKK1, overexpression of GSX2 and EBF1, two TFs essential for the development of striatal interneurons, actively suppresses the expression of the medial ganglionic eminence progenitor markers PAX6 and NKX2.1 and drives cell cycle exit. After 60 days of long-term differentiation, overexpression of both TFs finally results in MSN progenitor cells expressing ISL1- and CTIP2; by day 80, 38.8% of all cells co-express the MSN markers DARPP32 and CTIP2 ([@B32]). However, whether or not this TF combination would be capable of directly specifying undifferentiated PSCs to MSNs merits further investigation.

### Motor and Sensory Neurons {#S2.SS4.SSS4}

Motor neuron development and specification *in vivo* is relatively well studied (see reviews by [@B62] and [@B14]), and this knowledge was efficiently exploited for studies focusing on the *in vitro* generation of enriched MN populations, which are affected by degenerative diseases such as amyotrophic lateral sclerosis. [@B55] for instance, successfully combined NGN2-driven differentiation of SHH- and RA-treated human PSC-derived NPCs with overexpression of the MN lineage-specific markers ISL1 and LHX3 yielding 60% cells co-expressing the MN markers ISL1 and ChAT at day 13 of differentiation. In 2013, the group of Hynek Wichterle demonstrated that overexpression of this TF combination can also successfully specify the differentiation of mouse ESCs into spinal MNs directly, whereas cranial MNs can be obtained by replacing Lhx3 by Phox2a in this TF cocktail. A systematic comparison of these two different TF combinations by gene array analysis revealed a sharp decrease of pluripotency-associated genes *Oct4* and *Nanog* and an upregulation of pan-MN markers such as *Isl1*, *Ebf1* and *Ebf3* as well as the VAChT in both paradigms, whereas upregulation of *Tbx20*, *Phox2a*, *Phox2b*, *Rg4*, and *Gal* was only detected in neurons subjected to forward programming with Phox2a. The results of this study further indicate that these divergent outcomes are obtained because Isl1 is recruited to different genomic sites when co-expressed with Ngn2 in combination with either Lhx3 or Phox2a. Yet, both MN subpopulations become electrophysiologically functional and capable of forming cholinergic synapses after maturation on cortical mouse astrocytes ([@B99]). A few years later, [@B46] verified that Sendai virus-mediated overexpression of the TF cocktail NGN2, ISL1 and LHX3 in human PSCs, too, promotes the expression of MN markers. More specifically, only the full TF cocktail and the 2-factor combination of NGN2 and LHX3 but neither NGN2 in conjunction with ISL1 nor any of the single TFs resulted in MN derivation. Notably, after 3 weeks of differentiation NGN2/ISL1/LHX3-overexpressing neurons were electrophysiologically active and formed neuromuscular junctions with cultured myocytes ([@B46]). [@B28] expressed both TF combinations identified by Hynek Wichterle's group (NGN2/ISL1/LHX3 and NGN2/ISL1/PHOX2A) in human iPSCs via Piggy-bac transposable vectors. Concordant with the previous results, iPSCs downregulated the pluripotency marker *NANOG* and upregulated pan-MN genes such as *TUBB3*, *ISL1*, and *ChAT* within the first 3 days of differentiation. By day 5, *HB9* expression was increased when LHX3 was co-expressed, whereas *PHOX2B*, *TBX20*, and *RG4* were detected upon PHOX2A overexpression. Finally, the authors of this study functionally characterized the cranial MNs obtained after 12 to 13 days of NGN2/ISL1/PHOX2A overexpression and observed that these cells were capable of firing action potentials upon current stimulation, and almost half of all analyzed cells even displayed spontaneous glutamatergic postsynaptic currents ([@B28]).

Whilst these studies utilized joined overexpression of the neurogenic TF Ngn2 with MN lineage-associated TFs, [@B45] investigated whether overexpression of generic neurogenic TFs can induce specified neuronal subtypes when combined with fate-modulating extrinsic factors. Indeed, they found that overexpression of NGN1, NGN2, NGN3, NEUROD1, and NEUROD2 in human PSCs combined with RA, forskolin and dual SMAD inhibition via SB431542 and dorsomorphin yields highly pure neuronal cultures expressing the MN markers HB9, ISL1, and ChAT ([@B45]). Interestingly, the combination of NGN2 overexpression with forskolin and dorsomorphin treatment has been described to even convert human fibroblasts into cholinergic MNs ([@B86]).

On the other hand, [@B110] revealed that overexpression of the MN-associated TFs Phox2b and Olig2 in mouse ESC-derived, posterior-ventral NPCs suffices to specify visceral and somatic MNs, respectively. Further dissecting the role of Phox2 TFs in segregating MNs from other populations of hindbrain neurons, [@B102] overexpressed either Phox2a or Phox2b in Nestin-expressing ESC-derived NPCs. Although the expression of both TFs largely overlaps *in vivo*, the sequence of their expression is known to be important for the specification of different neuronal subtypes: Phox2a precedes Phox2b induction during the development of noradrenergic ([@B113]) and midbrain MNs ([@B114]), whereas in hindbrain visceral MNs, Phox2b is induced before Phox2a (see review by [@B16]). Knock-out studies further showed that although Phox2b expression can compensate for effects caused by Phox2a-knock-out in noradrenergic neurons of the locus coeruleus, it does not suffice to rescue the loss of MNs in the midbrain ([@B24]). *Vice versa*, Phox2a cannot completely compensate for Phox2b loss during the development of noradrenergic neurons and visceral MNs ([@B24]). Concordant with these findings, overexpression of both Phox2 TFs in mouse and human ESC-derived NPCs upregulated the expression of visceral MN markers as for instance *Isl1*, *Nkx6.2*, *Tbx2*, and *Tbx20* when combined with the morphogens Fgf8 and Shh. Conversely, combining Phox2b but not Phox2a overexpression with Bmp7 and Fgf8 treatment increased the expression of genes characteristic for noradrenergic neurons such as *Tfap2a*, *Dbh*, *Tlx3*, and *Net* ([@B102]).

Very recently, the group of Carsten Bönnemann published a protocol to derive sensory neurons from human iPSCs via forward programming. The authors demonstrated that even in the absence of neuronal lineage-promoting medium conditions, doxycycline-induced expression of NGN2 and BRN3A from the human genomic safe harbor locus *CLYBL* specifies human iPSCs toward a presumable human-specific neuronal subtype of glutamatergic sensory neurons responsive to cold as well as mechanical stimuli. This neuronal phenotype was also acquired when expression of this TF combination was induced in iPSC-derived neural crest progenitors for 14 days. Notably, when iPSC-derived neural crest progenitors were exposed to doxycycline for as short as 24 h, these cells adopted an exclusively PIEZO2-positive but TRPM8-negative touch-sensitive phenotype ([@B105]). This finding is in line with the observation that even a 24-h pulse of NGN2-only overexpression (in combination with a GDNF-based differentiation paradigm) is sufficient to direct human ESC-derived neural crest cells into highly enriched cultures of mechanoreceptive neurons ([@B129]).

In sum, whilst these studies impressively illustrate the potential of the forward programming technique to derive distinct neuronal subtypes, they also demonstrate the sensitivity of the approach to subtle alterations in TF combinations and co-administered growth and patterning factors.

Glial Cells {#S2.SS5}
-----------

Astrocytes are crucial for neuronal development, synaptogenesis and synaptic function, brain tissue homeostasis including energy and substrate distribution, and they provide the structural scaffold of the brain parenchyma. Oligodendrocytes are not only crucial for myelination but also axonal maintenance and even immunomodulation (reviewed by [@B78]). Given the plethora of glial functions that are essential for proper brain physiology, the role of these cells in the pathogenesis of neurodegenerative diseases becomes increasingly acknowledged, which contributes to the great interest in producing glial cells for basic and translational research in a fast and efficient manner by TF overexpression ([Table 2](#T2){ref-type="table"}).

###### 

Transcription factors used for promoting glial differentiation of neural precursor cells and pluripotent stem cells *in vitro*.

  Derived cell type   Starting cell type   Species   Transcription factor used for forward programming                         References
  ------------------- -------------------- --------- ------------------------------------------------------------------------- ----------------
  Astrocytes          NPCs                 Mouse     Emx2                                                                      [@B34]
                      NPCs                 Mouse     Rnf20                                                                     [@B85]
                      iPSC-derived NPCs    Human     NFIA                                                                      ^(17)^ [@B148]
                      PSCs                 Human     NFIB or NFIB+SOX9                                                         ^(18)^ [@B19]
                      PSCs                 Human     NFIA or NFIA+SOX9                                                         ^(16)^ [@B81]
  Oligodendrocytes    NPCs                 Mouse     Olig1                                                                     [@B6]
                      NPCs                 Mouse     Olig1 or Olig2 or Nkx2.2                                                  ^(19)^ [@B25]
                      NPCs                 Mouse     Ascl1 or Olig2 or Nkx2.2 or Ascl1+Olig2 or Ascl1+Nkx2.2 or Olig2+Nkx2.2   [@B139]
                      NPCs                 Mouse     Nkx2.2AS                                                                  [@B153]
                      NPCs                 Mouse     Olig1 or Olig2                                                            [@B91]
                      NPCs                 Mouse     Ascl1 or Olig2 or Sox10                                                   [@B13]
                      NPCs                 Mouse     Sox10                                                                     ^(24)^ [@B94]
                      NPCs                 Mouse     Lnc-158                                                                   [@B83]
                      NPCs                 Human     OLIG1 or OLIG2 or OLIG1+OLIG2                                             ^(21)^ [@B60]
                      NPCs                 Human     OLIG2                                                                     ^(20)^ [@B90]
                      NPCs                 Human     ASCL1 or NKX2.2 or OLIG2 or PRRX1 or SOX10                                ^(22)^ [@B161]
                      NPCs                 Human     OLIG1 or OLIG2 or OLIG1+OLIG2                                             [@B84]
                      iPSC-derived NPCs    Human     SOX10 or NKX6.2+OLIG2+SOX10                                               ^(23)^ [@B31]
                      PSC-derived NPCs     Human     SOX10                                                                     ^(25)^ [@B39]
                      iPSCs                Human     OLIG2+SOX10                                                               [@B80]
                      PSCs                 Human     SOX10 or OLIG2+SOX10                                                      [@B115]

Numbers in superscript relate to citations in

Figure 2

.

### Forward Programming to Astrocytes {#S2.SS5.SSS1}

As with neurons, astrocytes -- and even further specified astrocyte subtypes -- can be differentiated from PSCs by multi-step, growth factor-based protocols, which stimulate signaling pathways involved in astrogenesis after initial induction of a neuroectodermal fate (compare, e.g., the elegant protocol by [@B75]). Yet, growth factor-based protocols are usually complex and time-consuming, especially if they are aiming at creating non-reactive cells resembling quiescent astrocytes *in vivo*. Hence, there is a need for the derivation of functional astrocytes via forward programming. In primary mouse cortical NPCs, astrocytic commitment can be facilitated via induction of Stat3 by overexpression of Rnf20 ([@B85]). Overexpression of the TF Emx2 in mouse cortical NPCs regulates Egf and Fgf signaling, which are crucial for maintaining the pool of proliferating astrocyte progenitors ([@B34]).

In a landmark study, [@B19] lentivirally overexpressed the NFI TF family member NFIB alone or in combination with SOX9 in human PSCs. In this paradigm, PSCs differentiate into mature, post-mitotic astrocytes expressing markers such as GFAP, S100β, VIM, ALDH1L1, and GLAST within 21 days of differentiation. At this differentiation stage, astrocytes further contain glycogen-positive granules comparable to primary astrocytes. Functional assessments of these forward programmed astrocytes between days 14 and 21 of differentiation revealed that the derived cells exhibit typical characteristics of human adult astrocytes such as generation and propagation of spontaneous calcium waves, glutamate uptake, responsiveness to ATP and inflammatory stimuli such as IL-1β, the ability to form functional gap junctions with other astrocytes and the potency to promote synaptogenesis in a co-culture system with iPSC-derived forward programmed neurons ([@B19]).

Independent of and almost at the same time as the report by [@B19], the lab of Su-Chun Zhang published a protocol to derive functional astrocytes from human PSCs by doxycycline-inducible expression of NFIA, another NFI TF family member, via CRISPR/Cas9-mediated targeting of the human *AAVS1* genomic safe harbor locus. By overexpressing SOX9 in addition to NFIA, and combining this forward programming protocol with a conventional morphogen-driven astrocyte differentiation paradigm, the efficiency of astrocyte generation was significantly increased so that finally around 70% of all cells co-expressed the astrocyte markers GFAP and S100β at day 52 of differentiation. Similar to the astrocytes derived by [@B19], their cells could propagate calcium waves, take up free glutamate from the culture medium, and facilitate neurite outgrowth when co-cultured with human iPSC-derived neurons. Interestingly, the authors further reported that transgene induction during the first 10 days of differentiation was dispensable for successful astrocyte induction. Importantly, when they used this transgene induction-free window for morphogen-based patterning, they could generate diverse astrocytic subtypes (i.e., dorsal and ventral forebrain astrocytes as well as spinal astrocytes) within the same time frame ([@B81]).

Despite the many similarities between the protocols published by [@B19] and [@B81], it is noteworthy that the former protocol leads to the derivation of functional astrocytes much faster than the latter one (2--3 versus \>7 weeks). This might have several causes, including the choice of the TFs itself (NFIB versus NFIA), the methods used for TF delivery that could influence total gene dosage (lentiviral expression versus expression from the endogenous *AAVS1* locus) and the efficiency of the concomitant growth factor regimen (e.g., sequential versus combined exposure to FGF and EGF). Thus, the results of these two studies stress the context-dependency of TF-based forward programming. This is further nicely exemplified by the fact that NFIA was recently demonstrated to act as a gliogenic switch in iPSC-derived NPCs, too, facilitating the fast generation of astrocytes in combination with glia-promoting, LIF-containing medium. Continued overexpression of this TF, however, inhibited astrogenesis from NPCs, probably by inducing premature G1 cell cycle arrest ([@B148]). Surprisingly, overexpression of the long non-coding RNA lnc-158, which is an endogenous antisense RNA of *NFIB* and positively regulates NFIB levels, has been reported to promote the differentiation of primary mouse NPCs into oligodendrocytes instead of astrocytes ([@B83]).

### Promoting Oligodendrogenesis by Transcription Factor Overexpression {#S2.SS5.SSS2}

[@B161] screened 5 TFs (NKX2.2, OLIG2, PRRX1, ASCL1, and SOX10) known to be associated with oligodendrocyte lineage commitment and analyzed their potency to induce OPC markers in primary human NPCs. Whilst all examined TFs repressed astrocytic genes, NKX2.2 and especially ASCL1 induced the expression of neuronal genes in addition to the upregulation of OPC markers. Gene set enrichment analyses of RNA sequencing data further revealed that only SOX10 overexpression induced genes expressed in both primary mouse and human OPCs, whereas ASCL1-induced OPCs expressed markers resembling mouse but not human OPC fate. The authors further demonstrated the superiority of SOX10-induced OPCs by the fact that only this population could be cultured *in vitro* for several passages whilst maintaining its oligodendrocyte differentiation potential ([@B161]). In line with the results of [@B161] are various other reports from different groups demonstrating the oligodendrocyte-promoting effects of Ascl1 in combination with Olig2 or Nkx2.2 ([@B139]), as well as Ascl1 ([@B13]), Olig1/2 ([@B6]; [@B25]; [@B139]; [@B60]; [@B90], [@B91]; [@B13]; [@B84]), Nkx2.2 ([@B25]; [@B139]; [@B153]) and Sox10 ([@B13]; [@B31]; [@B39]; [@B94]) alone. Interestingly, overexpression of Ascl1 *in vivo* has also been shown to coax endogenous hippocampal NPCs into an oligodendroglial, myelination-competent phenotype ([@B61]; [@B13]).

[@B31] demonstrated that overexpression of SOX10 alone can induce oligodendrocyte differentiation of cultured human iPSC-derived NPCs. Yet, oligodendrocyte derivation is more efficient when SOX10 is overexpressed in combination with OLIG2 and NKX6.2. With this improved protocol, around 60% to 80% of all cells stain positive for GALC and O4 at day 28 of differentiation and O4-enriched oligodendrocytes exhibit the capability to myelinate iPSC-derived neurons after 3 weeks of *in vitro* co-cultivation ([@B31]). One year after the report of [@B31], also the group of Catherine Verfaillie published a protocol to derive oligodendrocytes from human PSC-derived NPCs by lentiviral SOX10 overexpression: [@B39] performed RNA sequencing analysis of purified O4-positive cells at day 22 of differentiation, demonstrating that their protocol gives rise to oligodendrocytes that highly resemble intermediate to mature primary human brain-derived oligodendrocytes. Moreover, purified O4-positive oligodendrocytes were able to myelinate human iPSC-derived neurons after 20 days of co-culture. Finally, [@B39] created a stable human ESC-line with doxycycline-inducible expression of SOX10 from the endogenous *AAVS1* locus and demonstrated that this approach successfully generates mature oligodendrocytes when transgene expression is induced at the NPC stage. Noteworthy, however, doxycycline-induced expression of SOX10 at the ESC stage was insufficient to give rise to MBP-expressing oligodendrocytes ([@B39]).

Whereas these studies have identified multiple routes to promote oligodendrocyte differentiation from an NPC stage, direct TF-driven specification of PSCs toward the oligodendrocyte lineage has remained more challenging to achieve. [@B80] reported that combining a multi-step growth factor-based differentiation protocol with SOX10 and OLIG2 overexpression in human iPSCs results in cultures consisting of around 40% O4-positive oligodendrocytes after 4 weeks of differentiation. However, when co-culturing SOX10/OLIG2-induced OPCs with embryonic primary rat cortical neurons, only around 5% of all cells stained positive for O4 at day 14 of co-culture and just 0.5% of all rat axons co-labeled with processes extending from human forward programmed oligodendrocytes ([@B80]). One year later, the group of Mark Kotter published a highly controlled SOX10 and OLIG2-driven forward programming protocol for the derivation of oligodendrocytes from human PSCs, which is based on inducible transgene overexpression by dual genomic safe harbor targeting (i.e., targeting the doxycycline-responsive transcriptional activator to the *ROSA26* and the tetracycline-responsive element-regulated transgenes of interest to the *AAVS1* locus). Interestingly, using this system, the authors could generate proliferative OPCs, which terminally differentiated into almost pure cultures of oligodendroglial cells expressing characteristic markers such as CNP and PLP upon mitogen withdrawal ([@B115]).

It will be interesting to investigate whether TFs and TF combinations explored in the context of fibroblast-to-glia transdifferentiation can be exploited for forward programming of PSCs. For instance, direct cell fate conversion of rodent fibroblasts into OPCs was achieved by combined overexpression of the TFs Sox10 and Olig2 with either Nkx6.2 ([@B103]; [@B94]) or Zfp536 ([@B168]). Similarly, myelination-competent Schwann cells can be derived from mouse and human fibroblasts via the combined overexpression of Sox10 and Krox20 ([@B98]; [@B137]) and have been shown to accelerate nerve regeneration and motor recovery after transplantation into mice with sciatic nerve transection ([@B137]).

Taken together, the results of these studies underpin the potency of some TFs and/or TF combinations for oligodendrocyte specification. Yet, the efficient direct specification of oligodendrocytes form a PSC state deserves further attention. In addition to TFs, miRNAs could be supportive in this process. The miRNAs miR-219 and miR-338 were shown to promote oligodendrocyte maturation by targeting inhibitors of oligodendrogenesis such as Sox6 and Hes5, as well as promoters of neurogenesis as for instance Neurod1, Isl1, Otx2, and Zfp238/RP58 ([@B173]).

*In vivo* Application of Forward Programmed Cells: Insights From Transplantation Studies {#S3}
========================================================================================

As a proof-of-concept for the general applicability of forward programmed cells for neuroregenerative approaches, these cells can be transplanted into healthy animals and monitored for graft survival, maturation and integration ([Figure 2](#F2){ref-type="fig"}). Along this line, [@B172] demonstrated that 6 weeks after transplanting human immature neurons (7 days after infecting ESCs with a lentivirus encoding for NGN2) into the mouse striatum, the grafted cells adopted a neuronal phenotype exhibiting dendritic arborizations, axonal outgrowth and electrophysiological functionality, and received inhibitory synaptic input from host striatal interneurons ([@B172]). [@B171] transplanted human PSC-derived NPCs, forward programmed by LHX6 overexpression, into the ventral mouse forebrain. Surprisingly, the authors observed that the number of GABAergic interneurons overall was not significantly increased in the doxycycline-induced, forward programmed grafts as compared to uninduced control transplants, and LHX6-overexpressing as well as uninduced control grafts differentiated into all four interneuron subtypes. Still, the forward programmed neurons exhibited spontaneous electrophysiological activity and postsynaptic currents reflecting mostly inhibitory GABAergic input ([@B171]), demonstrating that forward programmed neurons can -- in principal -- exhibit proper functionality upon grafting. This notion is substantiated by reports of several other groups: For instance, 14-day-old neurons, derived from human PSCs by ASCL1- and DLX2-overexpression, survive transplantation into the subventricular zone and cerebral cortex of neonatal mice and mature into GABAergic neurons within 3 months post transplantation ([@B167]), and neurons derived from human PSCs by combined ASCL1, DLX2 and LHX6 overexpression mature into GABAergic neurons *in vivo*, too ([@B140]). Notably, 2 months after grafting, these GABAergic neurons had functionally integrated into cortical layers V and VI, exhibiting repetitive action potential firing and receiving synaptic input from host neurons ([@B140]). In an elegant study by the group of Hynek Wichterle, MNs were programmed by overexpressing Ngn2 and Isl1 in combination with either Lhx3 or Phox2a in mouse ESCs, and the resulting cells were grafted into the cervical and brachial tube of chicken embryos 2 days after transgene induction. Already 2 days after transplantation, the grafted cells had spatially segregated and exhibited axonal projections concordant with their MN subclass identity: Like spinal MNs, Ngn2/Isl1/Lhx3-overexpressing cells accumulated in axial and limb nerve branches and exhibited substantial axonal outgrowth from the ventral root of the spinal cord, whereas Ngn2/Isl1/Phox2a-derived neurons accumulated in the lateral spinal cord and projected axons toward the spinal accessory nerve resembling cranial MNs ([@B99]).

![*In vivo* applications of cell types derived by forward programming. Numbers in superscript relate to references cited in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}.](fncel-14-00121-g002){#F2}

Whilst transplantation into unlesioned healthy recipients can be a highly useful tool to assess the *in vivo* differentiation and function of forward programmed neurons, studies in the context of a disease model can provide information on their regenerative capacity. First milestones to use forward programmed neurons for experimental neuroregeneration were already achieved as early as 2002, when [@B69] transplanted Nurr1-overexpressing mouse ESC-derived neurons in the striatum of 6-OHDA-lesioned rats, an animal model of PD. 4 to 8 weeks post transplantation, the majority of transplanted cells expressed the dopaminergic marker TH, and 5 out of 6 grafts exhibited spontaneous postsynaptic currents. Most importantly, the authors demonstrated that animals transplanted with Nurr1-overexpressing neurons showed improved behavioral recovery compared to animals receiving sham injections or grafts of wild-type cells ([@B69]). [@B93] reported a few years later that Nurr1/Pitx3-induced mouse and human ESC-derived NPCs grafted into the striatum of 6-OHDA-lesioned mice resulted in a significant reduction in apomorphine-induced rotation behavior compared to the transplantation of control vector-transduced cells. However, further immunohistochemical analyses of the grafts revealed that in their setting, neurons retained an immature morphology with only a minority of them expressing TH ([@B93]). In accordance with this finding, [@B150] more recently showed that 12 days after transplanting immature dopaminergic neurons (8 days post inducing ASCL1, NURR1 and LMX1A in human iPSCs) 4 out of 6 grafts survived, and only a fraction of the surviving cells displayed neuronal morphologies and expression of TH ([@B150]). Similar results were reported by [@B70], who demonstrated that although transplantation of rat wild-type midbrain NPCs improves behavior of 6-OHDA-lesioned rats, transplantation of Nurr1-overexpressing midbrain or cortical NPCs does not, presumably because Nurr1-NPC grafts contained fewer TH-positive neurons which additionally exhibited immature morphologies ([@B70]). Whilst these findings were confirmed by [@B111], their study further revealed that 8 weeks after transplanting rat NPCs overexpressing a combination of Nurr1, Ascl1 and Shh or Nurr1, Bcl-XL and Shh, dopaminergic specification and dopamine levels are increased and motor deficits decreased compared to transplantation of NPCs overexpressing Nurr1 alone ([@B111]). In a study by [@B38] only 50% of all grafts survived after transplanting mouse Lmx1a-overexpressing ESC-derived NPCs into 6-OHDA-lesioned rats. In these grafts, the majority of the transplanted cells co-expressed the dopaminergic markers TH, Pitx3, En1/2, Lmx1a and Vmat, and even non-overlapping positivity for Girk2 and calbindin, indicating generation of both, substantia nigra A9 neurons and ventral tegmental area A10 dopaminergic neurons ([@B38]). Lastly, NPCs derived from ESCs via forward programming with Lmx1a differentiate into TH, DAT and GIRK2-expressing dopaminergic neurons *in vivo*, too ([@B128]).

In addition to PD, HD is intensely explored as a candidate disease for neural cell replacement. Since striatal MSNs are the main target of the disease, fast and efficient *in vitro* generation of MSNs is a key prerequisite for a cell therapeutic approach. [@B32] grafted human ESC-derived NPCs carrying inducible GSX2 and EBF1 transgenes into the quinolinic acid-lesioned striatum and observed that 2 months after transplantation, these NPCs had differentiated into GABAergic neurons expressing the striatal MSN markers CTIP2 and DARPP32 and extending projections toward the substantia nigra ([@B32]). However, comparable to what has been observed after transplantation of forward programmed dopaminergic neurons ([@B150]), the number of CTIP2-positive human neurons was not different in GSX2/EBF1-overexpressing transplants versus uninduced control grafts ([@B32]). It remains to be investigated whether or not MSNs directly forward programmed from the PSC stage would survive and integrate upon transplantation.

Forward programmed glial cells might be valuable for neuroregenerative interventions, too. For astrocytes, however, there are only few published reports about the general feasibility of grafting these cells. Yet, these reports demonstrated that forward programmed astrocytes maintain their cellular identity up to 3 months after grafting ([@B83]a; [@B148]) and exhibit astrocyte-specific traits *in vivo* such as their affinity to blood vessels and the formation of functional gap junctions with host astrocytes ([@B19]). For oligodendrocytes, [@B25] reported that Olig2-expressing mouse NPCs grafted into the demyelinated mouse striatum differentiate into mature MBP-positive oligodendrocytes engaging in remyelination ([@B25]). In line with this, [@B60] demonstrated that OLIG2-expressing NPCs survive transplantation into contused spinal cord better than wild-type NPCs and exhibit increased proliferation and migration into white matter tissue, where they efficiently differentiate into MBP-positive oligodendrocytes promoting myelination. Potentially due to this pro-myelinating effect, transplantation of OLIG2-NPCs improves locomotion after contusive injury compared to sham injection or transplantation of wild-type NPCs ([@B60]). Also in Shiverer/Rag mice, which are used as models for myelination disorders, NPCs overexpressing OLIG2 ([@B90]) or SOX10 ([@B161]; [@B94]) have been shown to differentiate into MBP-positive oligodendrocytes exhibiting ensheathment of host axons. Transplantation of more mature O4-positive oligodendrocytes, which were derived from human NPCs by SOX10 overexpression, promotes myelination in brain slices of Shiverer/Rag mice as well ([@B39]). In an elegant study, [@B31]. demonstrated that magnetic activated cell sorting (MACS)-purified O4-positive oligodendrocytes (14 days after induction of the TFs SOX10, OLIG2, and NKX6.2 in human NPCs) not only promote the formation of normally compacted MBP-positive sheaths with nodal structures around host neurons 16 weeks post transplantation but are also capable of remyelination after neurotransplantation in Shiverer/Rag mice treated with the membrane-dissolving chemical lysophosphatidyl-choline, which induces completely demyelinated lesions in white matter tissue ([@B31]). However, since all of these transplantation studies were conducted with OPCs or oligodendrocytes derived by TF overexpression in NPCs, there is no proof so far that oligodendrocytes forward programmed from PSCs can survive neurotransplantation. This certainly merits further investigations, since OPCs directly converted from somatic fibroblasts were demonstrated to be capable of differentiating into myelinating oligodendroglial cells after transplantation into the brain of Shiverer/Rag mice, too ([@B103]; [@B168]).

Forward Programming of PSCs Versus Primary Cell Fate Conversion {#S4}
===============================================================

Since forward programming of PSCs can be regarded as a fallout of the technological advances of somatic cell reprogramming into iPSC and direct interconversion of somatic cells within and across germ layers, it is interesting to reflect on the commonalities and differences of these *in vitro* approaches. From a mechanistic point of view, direct cell fate conversion can be segregated into two different phases, which has been nicely deciphered in several milestone publications in the context of transdifferentiating fibroblasts into neurons via Ascl1, Brn2, and Myt1l overexpression ([@B158]; [@B162]; [@B157]; [@B92]). Here, the fibroblast's chromatin landscape has to be remodeled first in order to become permissive to TF binding at neuron-specific genes. This chromatin opening can be mediated by small molecules acting as epigenetic modifiers, or induced by cell type-specific pioneer TFs, which -- by definition -- are able to bind to and open up closed chromatin. Second, following the necessary epigenetic rearrangements, the transcriptional landscape has to be modulated in order to activate neuronal genes and inhibit the acquisition of alternative fates, including the repression of fibroblast-specific transcriptional signatures. Notably, many principles regulating the acquisition of a new cell fate during transdifferentiation seem to apply to forward programming, too. [@B3] recently analyzed how Ngn2 and Ascl1 specify mouse ESCs into neurons and demonstrated that both bHLH TFs act as neuronal pioneer TFs binding to genes which are in closed chromatin states in ESCs. By this, Ngn2 and Ascl1 induce and recruit secondary pro-neural TFs such as Brn2, thereby promoting the acquisition and stabilization of a neuronal fate. Interestingly, and in accordance with other publications, [@B3] further report that despite the high similarity of the mechanistic action of these two TFs, Ngn2 and Ascl1 induce quite distinct neuronal programs as the binding patterns of both TFs in ESCs are largely divergent.

Although the general principles underlying forward programming and direct cell fate conversion seem to be quite similar, there are some differences which need to be highlighted ([Table 3](#T3){ref-type="table"}). First, the epigenetic hurdles that have to be overcome for the proper activation of an alternative transcriptional program seem to be lower in PSCs than in terminally differentiated somatic cells (in particular in the case of a trans-germ layer conversion). Thus, although Ascl1, for instance, is sufficient to specify PSCs into neurons, it is comparably inefficient to convert fibroblasts into authentic iNs when overexpressed alone ([@B88]), and Ngns or Neurods, which are commonly used in forward programming paradigms, seem almost incapable of converting fibroblasts into iNs ([@B21]; [@B88]). Second, from a time perspective, the derivation of neuronal cells from somatic cells is faster via the direct conversion route compared to forward programming via the iPSC stage: In this scenario, transdifferentiation is a one-step-procedure, whereas for forward programming, somatic cells have to be first reprogrammed into iPSCs before they can be differentiated into the desired somatic cell type by TF overexpression. However, due to the intermediate pluripotent stage, the forward programming route is scalable at the iPSC stage and can give rise to highly homogeneous cell batches. Notably, it is still not completely resolved whether forward programming of PSCs involves a stable NPC intermediate, since upregulation of NPC-associated markers was reported to be very short-lasting ([@B172]; [@B18]). Likewise, transient activation of an NPC-like transcriptional program was recently described in the context of direct pericyte-to-neuron conversion ([@B65]). Interestingly, however, single cell-RNA sequencing of neural cultures derived from human PSCs via NGN2 overexpression recently indicated that even after culturing these cells in neuronal differentiation-promoting medium on mouse glia, a significant fraction of cells can remain in an NPC-like stage resisting neuronal maturation ([@B104]). Third, in contrast to forward programming from homogenous iPSC batches, every iN represents a single, post-mitotic direct cell fate conversion event. This means that transdifferentiation-derived cultures represent a mosaic of a vast number of single conversion events, which severely limits the degree of standardization that can be reached with an iN approach. Furthermore, since neurons are post-mitotic, the cell yield of an iN conversion is always limited by (i) the number of starting cells and (ii) the efficiency of the direct conversion approach. However, these drawbacks do not equally apply to all transdifferentiation paradigms. Instead of deriving terminally differentiated iNs, direct cell fate conversion can be used to generate induced neural stem cells (iNSCs; [@B51]; [@B121]; [@B131]; [@B132]) induced neuronal-like NPCs (iNPCs; [@B44]), or even iNPCs which are already primed to differentiate toward a specific neuronal subtype such as dopaminergic neurons ([@B152]). As these cells are stably self-renewing, especially iNSC cultures are almost as scalable and homogeneous as PSCs. Yet, direct conversion into iNSC/iNPCs has the drawback that, as with forward programming, it has to be followed up by a subsequent terminal differentiation step. Here, it is tempting to consider translating previous approaches on facilitating the differentiation of primary or PSC-derived NPCs by TF overexpression to iNSCs/iNPCs. A key issue in all these scenarios remains cell type authenticity, which can be compromised if the converted cells retain a significant degree of epigenetic and transcriptomic memory relating to the fate but also the age of the cell of origin. This memory seems to be largely maintained in fibroblast-derived iNs of different donor ages ([@B101]; [@B170]; [@B59]; [@B146]; [@B71]), whereas it is almost completely reset in iPSCs ([@B119]; [@B89]; [@B107]). Recently, directly converted iNSCs were shown to largely reset age-associated cellular signatures, too ([@B132]).

###### 

Comparative summary of key features important for cell fate engineering.

                                                      Forward programming              Direct cell fate conversion
  --------------------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------
  *Epigenetic barriers for reprogramming*             Low                              High
  *Scalability*                                       High                             Limited depending on proliferative potential of converted product
  *Degree of standardization that can be reached*     High                             Limited depending on proliferative potential of converted product
  *Preservation of somatic and age memory*            Low                              Potentially high
  *Possible translation into clinical applications*   Indirect (via transplantation)   Direct and indirect (via *in situ* conversion and transplantation of converted cells)

Prospects of Direct Cell Fate Conversion *in vivo* {#S4.SS1}
--------------------------------------------------

Direct cell fate conversion cannot only be achieved *in vitro* but also directly *in vivo*. While this concept is distinct from classic forward programming and has received its own coverage in several recent reviews ([@B53]; [@B47]; [@B138]; [@B7]; [@B35]; [@B116]), it might eventually provide a short-cut for brain repair bypassing a transplantation step and is thus worth mentioning here. Several studies have shown that such a transdifferentiation step can be triggered *in vivo* by the direct administration of reprogramming cues like TFs and/or miRNAs to resident rodent brain cells such as astrocytes ([@B17]; [@B77]; [@B49]; [@B33]; [@B43]; [@B87]; [@B155]; [@B40]) and NG2-positive glial cells ([@B49]; [@B52]; [@B155]; [@B40]). In this context, the group of Ernest Arenas demonstrated that even the *in vivo* conversion of mouse astrocytes into clinically relevant neuronal subtypes such as midbrain dopaminergic neurons is feasible. The authors overexpressed a TF cocktail comprising Ascl1, Lmx1a, Neurod1, and miRNA-218 in mouse brain astrocytes by stereotactic lentivirus injection and revealed that this does not only successfully elicit transdifferentiation but finally also corrects basal and postsynaptic deficits in dopamine transmission and improves spontaneous motor behavior deficits in 6-OHDA-lesioned PD mice ([@B122]). Importantly, the group of Magdalena Götz recently revealed that *in vivo* conversion of mouse cortical astrocytes into neurons can preserve region-and even layer-specific identities ([@B97]). This study also impressively underpins the relevance and potential impact of subspecification within the glial lineage. Lastly, it has recently been shown that *in vivo* cell fate conversion can even be extended beyond germ layer boundaries: [@B95] reported that brain-resident microglia, which originate from the yolk sac, are amenable to neuronal conversion in the mouse brain ([@B95]). A special variant of the *in vivo* conversion concept is the idea to transplant somatic cells that are already engineered to overexpress specific TFs upon an inducing stimulus and can thus be activated to convert *in situ* ([@B156]). Taken together, these reports underline the enormous biomedical potential of both, direct *in vitro* and *in vivo* conversion of somatic cells.

Challenges for Future Clinical Application {#S5}
==========================================

Cell Type Subspecification, Authenticity, and Maturity {#S5.SS1}
------------------------------------------------------

Forward programming comes with the significant benefit of being fast enough to be able to provide autologous cells from human patients for cell replacement therapies. However, on the benchwork side, one significant limitation of some currently available forward programming protocols is the reduced purity of the obtained cultures, especially when it comes to deriving highly specified neuronal subtypes. In some cases, subspecification might be augmented by the use of morphogens and small molecules. On the one hand, these molecules can help to properly regionalize (intermediate) NPC stages, as they might provide additional phenotype-instructing differentiation cues, which could otherwise only be delivered by combining several TFs upstream of the lineage-relevant signaling pathways. This was nicely exemplified by the group of Johan Ericson and Thomas Perlmann, who showed that overexpression of Lmx1a in ESC-derived mouse NPCs suffices to instruct dopaminergic neuron differentiation when combined with Shh and Fgf8 treatment, whereas caudalized NPCs only adopt a dopaminergic phenotype if the three midbrain-associated TFs Lmx1a, En1, and Otx2 are overexpressed in combination ([@B110]). On the other hand, small molecules might act as epigenetic modifiers and facilitate forward programming by either re-activating lineage-instructive genes, which are in an unfavorable epigenetic state or even completely silenced in PSCs, or by repressing alternative lineages (similar to the mode of action that has been described for the TF EZH2; [@B88]). In direct cell fate conversion, for instance, iN derivation from human fibroblasts via NGN2 overexpression is only successful if combined with the treatment with two small molecules, namely forskolin and dorsomorphin, which modulate chromatin accessibility at NGN2 target sites ([@B86]; [@B134]).

Another challenge for the clinical application of forward programmed cells might be the degree of cellular authenticity and maturity that can be achieved. One way to improve neuronal maturation *in vitro* is to co-culture forward programmed neurons with glial cells. Notably, the species from which the glial cells are retrieved might influence their maturation-promoting effect: In a recent study, culturing human glutamatergic neurons (differentiated via a classical morphogen-based approach) on mouse astrocytes was found to be superior to co-culture with rat astrocytes, whereas co-culture with human astrocytes did not support neuronal survival beyond 4 weeks. Interestingly, GABAergic neurons did not show this selective response to glial co-culture ([@B120]), and whether or not these effects also apply to forward programmed neurons is still to be determined.

Further studies are also required in order to clarify to what extent forward programmed neurons resemble their physiological *in vivo* counterparts. For example, in a recent study 4-week-old NGN2-forward programmed human neurons grown in an autapse setting displayed surprising morphological and functional properties, including systematic multi-peak excitatory postsynaptic currents originating from neurons possessing multiple axons, which were evident in about 25% of all cells analyzed ([@B100]; [@B120]). Increased axonal lengths and small diameters contributed to the observed phenomenon, and further resulted in extended synaptic delays as compared to mouse forebrain cortical neurons. Moreover, detection of a slow component contributing to these unusual electrophysiological kinetics indicated that the NGN2-neurons possess the ability to co-release GABA and glutamate from the same synapse ([@B120]). Although there are neurons *in vivo*, which grow multiple axons and/or co-release different neurotransmitters from the same synapse, these findings deserve further attention.

Transgene Delivery, Stability of Programmed Phenotypes and Safety {#S5.SS2}
-----------------------------------------------------------------

From a translational perspective, extrinsic factor-driven protocols, such as the delivery of differentiation cues by growth factors, morphogens and/or small molecules but also TF-based approaches employing mRNAs or proteins rather than integrating constructs might be easier to pass regulatory hurdles associated with the implementation of clinical trials. So far, however, most TF-based approaches have been relying on genetic modification of the target cell either by the use of integrating viruses or gene editing techniques such as CRISPR/Cas9. A main advantage of integrating a fate-instructing TF by techniques such as TALENs or CRISPR/Cas9 is better control on the integration site. Accordingly, some studies successfully integrated the forward programming-conveying TFs in the human genomic safe harbor *AAVS1* locus with high precision ([@B160]; [@B39]; [@B83]a; [@B100]; [@B120]). While integration-free methods such as mRNA ([@B45]; [@B96]; [@B164]) or protein delivery ([@B123]) are appealing, they come with their own pros and cons. For instance, mRNAs are rapidly translated but subsequently also timely degraded after entering the target cells, and significant protocol adaptations might be necessary to enable efficient transfection at all ([@B164]). Protein delivery, on the other hand, is technically challenging but also the only technique that circumvents potential post-translational regulation ([@B123]).

Another challenge is the maintenance of inducible transgene activation in the grafted cells until the point where the cellular phenotype of the transplanted cells becomes stable and transgene-independent. In principle, this could be tackled by grafting cells at later stages of *in vitro* specification. However, advanced pre-differentiation is typically associated with decreased survival and integration of the grafted cells. Thus, it might be beneficial to implement modalities for continuous delivery of TFs, e.g., by repetitive virus injection or slow-release depots in form of scaffolds binding or encapsulating fate-specifying proteins such as TFs and/or morphogens (see review by [@B15]). Prolonged provision of fate-specifying factors beyond the timepoint of transplantation might also enhance the *in vivo* stability of neuronal subtype identities: Although there are TF-based protocols available to produce quite specific neuronal subtypes *in vitro*, the results of several studies suggest that TF-mediated acquisition and maintenance of subtype specification might be less efficient in transplanted neurons compared to a pure *in vitro* scenario ([@B93]; [@B150]; [@B32]; [@B171]).

Another issue to be tackled when it comes to clinical transplantation is the fact that although grafting NPCs is more efficient than transplantation of terminally differentiated mature cells -- a notion particularly relevant for neurons (for a more comprehensive commentary, see [@B10]) -- transplantation of still immature cells such as differentiating PSCs and NPCs can increase the risk of uncontrolled overgrowth ([@B38]). While growth factor-based protocols might be more vulnerable to this complication, teratoma formation after transplantation has also been observed in the context of TF overexpression paradigms ([@B93]; [@B38]).

Concluding Remarks {#S6}
==================

TF overexpression in NPCs and TF-based forward programming of PSCs are valuable techniques to derive specialized and comparably mature neural cells within short time frames and thus provide powerful alternatives to classic growth factor-mediated PSC differentiation and direct (somatic) cell fate conversion. Besides generating precious insights into how cell fates are established and controlled by transcriptional and epigenetic regulation, one major asset of these approaches is that they can provide new donor sources for brain repair. Yet, a number of issues need to be addressed more deeply before forward programming can be implemented in a clinical setting.

Author Contributions {#S7}
====================

LF, KL, and OB contributed to the writing and editing of the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by grants from the European Union's FP7 Program (FP7-HEALTH-F4-2013-602278-Neurostemcellrepair) and Horizon 2020 Program (H2020-667301-COSYN), the German Federal Ministry of Education and Research (01EK1603A-Neuro2D3), the ERA-Net Neuron Program (01EW1812A-TREAT-SNGAP), and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, United States (R01NS100514). The content is solely the responsibility of the authors and does not necessarily represent the official views of these funding agencies.

All figures were created with the [BioRender.com](http://BioRender.com) online tool.

6-OHDA

:   6-hydroxydopamine

AAVS1

:   adeno-associated virus integration site 1

Aldh1a1

:   aldehyde dehydrogenase 1 family member a1

ALDH1L1

:   aldehyde dehydrogenase 1 family member L1

Aldh2

:   aldehyde dehydrogenase 2

AMPA

:   α-amino -3-hydroxy-5-methyl-4-isoxazolepropionic acid

Ascl1

:   achaete-scute homolog 1

Atoh1

:   atonal bHLH TF 1

ATP

:   adenosine triphosphate

Barhl1

:   BarH-like homeobox 1

Bcl-XL

:   B-cell lymphoma-extra large

bHLH

:   basic helix-loop-helix

Bmp

:   bone morphogenic protein

Brn2 aka POU3F2

:   POU domain class 3 transcription factor 2

Brn3a aka POU4F1

:   POU domain class 4 transcription factor 1

Brn4 aka POU3F4

:   POU domain class 3 transcription factor 4

ChAT

:   choline acetyltransferase

c-Myc

:   avian myelocytomatosis viral oncogene cellular homolog

CNP

:   2 ′,3 ′ -cyclic nucleotide 3 ′ -phosphodiesterase

CLYBL

:   citrate lyase beta like

CRISPR/Cas9

:   clustered regularly interspaced short palindromic repeats/Cas9

Ctip2 aka Bcl11b

:   B-cell lymphoma/leukemia 11b

Cux1

:   cut like homeobox 1

Dat

:   dopamine transporter

Darpp32 aka Ppr1b

:   protein phosphatase 1 regulatory subunit 1b

Dbh

:   dopamine beta-hydroxylase

Dkk1

:   Dickkopf-related protein 1

Dlk1

:   delta like non-canonical Notch ligand 1

Dll

:   distal-less

Dlx

:   distal-less homeobox

Dmrt5

:   doublesex and mab-3-related TF 5

Ebf

:   early B-cell factor

Egf

:   epidermal growth factor

Emx2

:   empty spiracles-homeobox 2

En

:   engrailed homeobox

ESC

:   embryonic stem cell

Ezh2

:   enhancer of zeste homolog 2

Fabp7

:   fatty acid binding protein 7

Fgf

:   fibroblast growth factor

Foxa2

:   forkhead-box-protein 2

Foxg1

:   forkhead box g1

Foxo1

:   forkhead box o1

GABA

:   gamma aminobutyric acid

Gal

:   galanin

GALC

:   galactosylceramidase

GDNF

:   glial cell-derived neurotrophic factor

GFAP

:   glial fibrillary acidic protein

Girk2

:   G-protein -related inward-rectifier potassium channel 2

Glast

:   glutamate aspartate transporter

Gpx1

:   glutathione peroxidase 1

Gsx2

:   genetic-screened homeobox 2

HB9

:   homeobox HB9

HD

:   Huntington's disease

Hes

:   hairy and enhancer of split

Il

:   interleukin

iN

:   induced neuron

iNPC

:   induced NPC

iPSC

:   induced pluripotent stem cell

Isl1

:   islet-1

Klf4

:   Krueppel-like factor 4

Krox20 aka Egr2

:   early growth response protein 2

Lhx

:   LIM homeobox

Lif

:   leukemia inhibitory factor

Lmx1

:   LIM homeobox TF 1

Map2

:   microtubule-associated protein 2

Mbp

:   myelin basic protein

MN

:   motor neuron

MSN

:   medium spiny neuron

Myod3

:   myogenic differentiation 3

Myt1l

:   myelin TF 1-like

Net

:   norepinephrine transporter

Neun

:   neuronal nuclei

Neurod

:   neurogenic differentiation

NfI

:   nuclear factor I

NG2

:   neuron-glial antigen 2

Ngn

:   neurogenin

Nkx2.1

:   homeobox protein NK-2 homolog A

Nkx2.2

:   homeobox protein NK-2 homolog B

Nkx6.2

:   homeobox protein NK-6 homolog B

NPC

:   neural precursor cell

Nr2f1

:   nuclear receptor subfamily 2 group f member 1

Ntn1

:   netrin 1

Nurr1

:   nuclear receptor related 1

O4 aka CLDN11

:   claudin 11

Oct3/4

:   octamer-binding TF 3/4

Olig

:   oligodendrocyte TF

OPC

:   oligodendrocyte progenitor cell

Otx

:   orthodenticle homeobox

Pax

:   paired box protein

PBX1

:   pre-B-cell leukemia TF 1

PD

:   Parkinson's disease

Phox2

:   paired like homeobox 2

PIEZO2

:   Piezo-type mechanosensitive ion channel component 2

Pitx3

:   pituitary homeobox 3

PLP

:   proteolipid protein

PRC2

:   polycomb repressive complex 2

Prrx1

:   paired related homeobox 1

PSC

:   pluripotent stem cell

RA

:   retinoic acid

REST

:   RE1 silencing TF

Rg4 aka UNC119

:   retinal protein 4

Rnf20

:   ring finger protein 20

ROSA

:   reverse oriented splice acceptor

S100 β

:   S100 calcium-binding protein β

Satb2

:   special AT-rich sequence-binding protein 2

Shh

:   sonic hedgehog

Smad

:   mothers against decapentaplegic

Sox

:   sex determining region Y-box

Stat3

:   signal transducer and activator of transcription 3

TALENs

:   transcription activator-like effector nucleases

Tbx

:   T-box TF

Tcf15

:   TF 15

TF

:   transcription factor

Tfap2a

:   TF AP-2 alpha

Th

:   tyrosine hydroxylase

Tlx3

:   T-cell leukemia homeobox 3

TRPM8

:   transient receptor potential cation channel subfamily melastatin member 8

Tubb3

:   class III β-tubulin

Tyrp1

:   tyrosinase-related protein 1

VAChT

:   vesicular acetylcholine transporter

vGLUT1

:   vesicular glutamate transporter 1

VIM

:   vimentin

Vmat

:   vesicular monoamine transporter

WNT

:   wingless-int

Zeb

:   zinc finger E-box -binding homeobox

Zfp

:   zinc finger protein.

[^1]: Edited by: Daniella Rylander Ottosson, Lund University, Sweden

[^2]: Reviewed by: Takumi Takizawa, Gunma University, Japan; Xiang Li, University of Wisconsin-Madison, United States

[^3]: This article was submitted to Cellular Neurophysiology, a section of the journal Frontiers in Cellular Neuroscience
